Your browser is no longer supported. Please, upgrade your browser.
EXAS Exact Sciences Corporation daily Stock Chart
Exact Sciences Corporation
Index- P/E- EPS (ttm)-0.77 Insider Own0.80% Shs Outstand148.15M Perf Week7.74%
Market Cap14.04B Forward P/E- EPS next Y-1.08 Insider Trans-7.94% Shs Float147.84M Perf Month8.91%
Income-106.60M PEG- EPS next Q-0.65 Inst Own90.40% Short Float9.00% Perf Quarter39.44%
Sales1.06B P/S13.22 EPS this Y55.40% Inst Trans0.14% Short Ratio8.64 Perf Half Y3.13%
Book/sh17.13 P/B5.43 EPS next Y46.30% ROA-3.70% Target Price101.79 Perf Year-19.98%
Cash/sh8.15 P/C11.40 EPS next 5Y- ROE-6.70% 52W Range35.25 - 123.99 Perf YTD0.54%
Dividend- P/FCF- EPS past 5Y12.50% ROI-1.90% 52W High-25.01% Beta1.92
Dividend %- Quick Ratio5.80 Sales past 5Y244.80% Gross Margin76.00% 52W Low163.76% ATR4.27
Employees4110 Current Ratio6.10 Sales Q/Q114.70% Oper. Margin-23.30% RSI (14)58.15 Volatility5.06% 4.70%
OptionableYes Debt/Eq0.61 EPS Q/Q-8.60% Profit Margin-10.00% Rel Volume0.85 Prev Close90.10
ShortableYes LT Debt/Eq0.60 EarningsJul 30 AMC Payout- Avg Volume1.54M Price92.98
Recom1.30 SMA206.12% SMA508.58% SMA20011.43% Volume1,316,284 Change3.20%
Apr-02-20Initiated Evercore ISI Outperform $70
Jan-10-20Resumed BTIG Research Buy $127
Jan-07-20Initiated Citigroup Buy $120
Dec-13-19Initiated Dougherty & Company Buy $120
Nov-15-19Initiated Stifel Buy
Oct-17-19Reiterated BofA/Merrill Buy $130 → $135
Oct-01-19Resumed Craig Hallum Buy $127
Sep-26-19Initiated Oppenheimer Outperform $130
Feb-26-19Upgrade Goldman Neutral → Buy $85 → $120
Oct-09-18Initiated UBS Buy
Sep-05-18Resumed The Benchmark Company Hold
Aug-13-18Reiterated Canaccord Genuity Buy $62 → $65
Apr-03-18Upgrade BTIG Research Neutral → Buy
Jan-29-18Initiated Goldman Neutral $51
Jan-08-18Reiterated The Benchmark Company Buy $60 → $65
Nov-13-17Downgrade Robert W. Baird Outperform → Neutral $56
Nov-01-17Downgrade BTIG Research Buy → Neutral
Oct-31-17Reiterated The Benchmark Company Buy $50 → $60
Oct-03-17Reiterated Canaccord Genuity Buy $45 → $60
Sep-21-17Reiterated Leerink Partners Outperform $45 → $50
Jul-12-20 12:00PM  
Jul-08-20 07:45AM  
Jun-16-20 03:09PM  
Jun-05-20 11:31AM  
Jun-03-20 09:49AM  
May-29-20 08:00AM  
May-26-20 06:00AM  
May-17-20 06:46AM  
May-12-20 03:10PM  
May-11-20 10:19AM  
May-07-20 11:30AM  
May-06-20 08:05PM  
May-05-20 10:30AM  
May-04-20 06:00AM  
May-03-20 07:36AM  
Apr-30-20 10:49AM  
Apr-29-20 12:34PM  
Apr-22-20 05:20AM  
Apr-08-20 05:51PM  
Apr-02-20 09:00AM  
Mar-26-20 05:45PM  
Mar-24-20 09:44AM  
Mar-21-20 09:22AM  
Mar-19-20 06:00AM  
Mar-17-20 05:45PM  
Mar-12-20 11:30AM  
Mar-04-20 07:37AM  
Feb-27-20 08:42AM  
Feb-25-20 08:28AM  
Feb-24-20 10:39PM  
Feb-19-20 05:44AM  
Feb-17-20 05:24AM  
Feb-12-20 03:52PM  
Feb-11-20 06:15PM  
Feb-04-20 06:41PM  
Feb-03-20 05:45PM  
Jan-27-20 05:50PM  
Jan-24-20 11:24AM  
Jan-23-20 01:30PM  
Jan-22-20 07:30AM  
Jan-21-20 06:31AM  
Jan-20-20 09:13AM  
Jan-17-20 09:15AM  
Jan-16-20 02:53PM  
Jan-15-20 09:36AM  
Jan-14-20 01:44PM  
Jan-13-20 01:51PM  
Jan-12-20 07:00PM  
Jan-07-20 10:08AM  
Jan-06-20 09:55AM  
Jan-02-20 06:00AM  
Dec-31-19 12:00AM  
Dec-26-19 12:05PM  
Dec-25-19 07:17AM  
Dec-24-19 11:30AM  
Dec-17-19 11:33AM  
Dec-16-19 06:53AM  
Dec-12-19 01:41PM  
Dec-04-19 08:35PM  
Nov-18-19 10:17AM  
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stenhouse MarkPresident, CologuardApr 03Sale56.6911,948677,33229,571Apr 06 04:41 PM
Stenhouse MarkPresident, CologuardApr 02Option Exercise0.0025,000041,519Apr 06 04:41 PM
Doyle James EdwardDirectorFeb 28Sale77.542,000155,08032,440Mar 03 07:20 PM
Conroy Kevin TPresident and CEOFeb 28Sale80.179,750781,658992,963Mar 02 07:13 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 28Sale80.172,383191,04558,578Mar 02 07:15 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 27Option Exercise0.005,025061,141Mar 02 07:15 PM
Conroy Kevin TPresident and CEOFeb 27Option Exercise0.0020,57501,002,713Mar 02 07:13 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 27Sale80.271,627130,59956,116Feb 28 04:37 PM
Stenhouse MarkPresident, CologuardFeb 27Sale80.271,05184,36416,519Feb 28 04:39 PM
Conroy Kevin TPresident and CEOFeb 27Sale80.2713,8751,113,746982,138Feb 28 04:36 PM
Conroy Kevin TPresident and CEOFeb 26Option Exercise0.0029,3370996,013Feb 28 04:36 PM
Stenhouse MarkPresident, CologuardFeb 26Option Exercise0.003,262017,570Feb 28 04:39 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 26Option Exercise0.003,436057,743Feb 28 04:37 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 25Sale85.114,910417,89054,307Feb 26 05:13 PM
Conroy Kevin TPresident and CEOFeb 25Sale85.1118,1151,541,768966,676Feb 26 05:11 PM
Conroy Kevin TPresident and CEOFeb 24Option Exercise0.0034,3250984,791Feb 26 05:11 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 24Option Exercise0.009,300059,217Feb 26 05:13 PM
Cole G BradleyGeneral Manager - DiagnosticsFeb 19Option Exercise35.7717,356620,77637,550Feb 21 04:58 PM
Cole G BradleyGeneral Manager - DiagnosticsFeb 19Sale100.0027,3562,735,60010,194Feb 21 04:58 PM
ORVILLE JACOB AGeneral Manager, New VenturesFeb 19Sale100.681,153116,0842,495Feb 20 05:55 PM
ORVILLE JACOB AGeneral Manager, New VenturesFeb 18Option Exercise0.003,64803,648Feb 20 05:55 PM
Hoof TorstenGeneral Manager, InternationalFeb 15Option Exercise0.002,09105,914Mar 27 04:15 PM
Cole G BradleyGeneral Manager - DiagnosticsJan 16Sale90.3010,000903,0008,653Jan 17 04:50 PM
Conroy Kevin TPresident and CEODec 16Option Exercise17.4811,440199,992950,466Dec 18 05:19 PM
Cole G BradleyGeneral Manager - DiagnosticsNov 21Sale80.3828,0162,251,92630,987Nov 25 05:18 PM
Johnson Scott C.SVP - Research and DevelopmentSep 12Sale108.633,527383,13812,311Sep 13 04:52 PM
Johnson Scott C.SVP - Research and DevelopmentSep 11Option Exercise0.007,500015,838Sep 13 04:52 PM
LEVANGIE DANIEL JDirectorJul 31Option Exercise5.3142,607226,42155,065Aug 02 04:24 PM
WYZGA MICHAEL SDirectorJul 31Option Exercise26.982,50067,45013,913Aug 02 04:25 PM
LEVANGIE DANIEL JDirectorJul 31Sale117.6442,6075,012,39812,458Aug 02 04:24 PM
Zanotti Katherine SDirectorJul 31Sale117.931,744205,67077,513Aug 02 04:28 PM
WYZGA MICHAEL SDirectorJul 31Sale117.935,000589,6508,913Aug 02 04:25 PM
Doyle James EdwardDirectorJul 31Sale117.932,808331,14734,440Aug 02 04:22 PM
Carey Thomas D.DirectorJul 31Sale117.6510,0001,176,48734,181Aug 02 04:20 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 30Sale105.609,8451,039,63249,917Jul 31 05:57 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 29Option Exercise0.0018,750059,762Jul 31 05:57 PM